Morbidity and quality of life following cytoreduction and HIPEC

Marcello Deraco, Dario Baratti, Shigeki Kusamura

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The evolution of locoregional therapy in the last 2 decades has changed the perpective in the clinical management of patients affected by peritoneal surface malignancies from mere palliation to possible cure [1]. Results from Phase II studies testing the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) in the treatment of peritoneal carcinomatosis (PC) of various origins have been encouraging [2]. In previous papers, we reported 5-year overall survival rates of 97% and 57%, respectively, for patients with pseudomyxoma peritonei [3] and malignant peritoneal mesothelioma [4-5] treated with CRS and HIPEC. Other authors have reported 5-year overall survival rates of 63.4% and 19%, respectively, in ovarian [6] and colorectal cancer [7]. Moreover, results of a phase III trial have confirmed the superiority of CRS and HIPEC in the treatment of patients with PC from colorectal cancer over other standard surgical and/or systemic chemotherapy (CT) modalities [8].

Original languageEnglish
Title of host publicationPeritoneal Carcinomatosis: A Multidisciplinary Approach
PublisherSpringer US
Pages403-418
Number of pages16
ISBN (Print)0387489916, 9780387489919
DOIs
Publication statusPublished - 2007

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Deraco, M., Baratti, D., & Kusamura, S. (2007). Morbidity and quality of life following cytoreduction and HIPEC. In Peritoneal Carcinomatosis: A Multidisciplinary Approach (pp. 403-418). Springer US. https://doi.org/10.1007/978-0-387-48993-3_26